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Tenofovir-Associated Nephrotoxicity in Two HIV-Infected Adolescent
Males
Abstract
We report two cases of tenofovir (TDF)-associated nephrotoxicity in perinatally HIV-infected adolescents.
The first case, a 16-year-old African American male with an absolute CD4+ cell count of 314 cells/mm3,
presented with an abrupt rise in serum creatinine leading to irreversible renal failure while on TDF-containing
highly active antiretroviral therapy (HAART). While the patient had evidence of underlying kidney disease,
the timing of his renal failure indicates that TDF played a central role. The second case, a 16-year-old African-
American male with an absolute CD4+ cell count of 895 cells/mm3, presented with rickets and
hypophosphatemia while receiving TDF-based HAART. To our knowledge, these cases represent the first
reports of TDF-associated irreversible renal failure and rickets in pediatric patients. We believe these cases
highlight important and potentially irreversible side effects of this agent and emphasize the need for further
studies of the renal safety of TDF in pediatric patients.
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Case Report
Tenofovir-Associated Nephrotoxicity in Two HIV-Infected
Adolescent Males
Sarah M. Wood, M.D.,1 Samir S. Shah, M.D., MSCE,2,3,5 Andrew P. Steenhoff, M.B., B.Ch.,3,5,6
Kevin E.C. Meyers, M.D.,4 Bernard S. Kaplan, M.B., B.Ch.,4 and Richard M. Rutstein, M.D.1,2
Abstract
We report two cases of tenofovir (TDF)-associated nephrotoxicity in perinatally HIV-infected adolescents. The
first case, a 16-year-old African American male with an absolute CD4þ cell count of 314 cells=mm3, presented
with an abrupt rise in serum creatinine leading to irreversible renal failure while on TDF-containing highly
active antiretroviral therapy (HAART). While the patient had evidence of underlying kidney disease, the timing
of his renal failure indicates that TDF played a central role. The second case, a 16-year-old African-American
male with an absolute CD4þ cell count of 895 cells=mm3, presented with rickets and hypophosphatemia while
receiving TDF-based HAART. To our knowledge, these cases represent the first reports of TDF-associated
irreversible renal failure and rickets in pediatric patients. We believe these cases highlight important and po-
tentially irreversible side effects of this agent and emphasize the need for further studies of the renal safety of
TDF in pediatric patients.
Introduction
Tenofovir disoproxil fumarate (TDF), a nucleotidereverse transcriptase inhibitor, received Federal Drug
Administration (FDA) approval for use in adult patients in
October 2001. TDF is often used to treat older children and
adolescents, particularly those receiving salvage regimens,
although it is not FDA approved for use in patients under the
age of 18. However, data from 2005 for a multisite pediatric
study group revealed that 13% of patients younger than 18
years of age were on a TDF-containing regimen (R.M. Rut-
stein, personal communication, 2006). TDF is a structural
analogue of cidofovir and adefovir, both of which have been
associated with significant renal dysfunction.1,2 Initial adult
clinical trials of TDF yielded no episodes of renal failure or
significant (grade 3 or 4) increases in serum creatinine con-
centration,3,4 and a recent review of adult expanded access
and postmarketing data indicated an overall low rate (0.5%)
of renal serious adverse events.5 However, recent cohort
studies have demonstrated decreases in creatinine clearance
(CrCl) and glomerular filtration rate (GFR) for adult patients
on TDF-containing regimens.6,7 Several reports have also
described TDF-associated renal failure in adults, most often
presenting as proximal tubular dysfunction with or without a
Fanconi-like syndrome.8–10
TDF-associated nephrotoxicity may occur as a consequence
of multiple drug interactions. The drug is primarily cleared
through renal excretion, entering the basal membrane of the
tubule cell via the human organic anion transporter 1 (hOAT1)
and exiting the apical cellular membrane through the multi-
drug–resistance transporter 4 (MRP 4).11 Drug interactions at
the cellular level may be responsible for the nephrotoxic po-
tential of TDF. Most reported cases of TDF-associated renal
failure have occurred in patients receiving concomitant treat-
ment with the protease inhibitor ritonavir (RTV).10 TDF
clearance is slower in subjects receiving lopinavir=ritonavir
(LPV=RTV), which may lead to accumulation of toxic drug
levels within tubular cells.12 Didanosine (ddI), a nucleoside
reverse transcriptase inhibitor (NRTI), has also been associ-
ated with an increased risk of nephrotoxicity with TDF due
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both to its renal excretion as well as possible competition for
hOAT1.9
We report two presentations of clinically significant TDF-
associated nephrotoxicity in adolescent patients receiving
TDF along with LPV=RTV.
Patient 1
A 16-year-old African American male with perinatally ac-
quired HIV and a history of tetralogy of Fallot presented with
an abrupt rise in serum creatinine concentration while re-
ceiving a TDF-containing HAART regimen. The patient’s
Center of Disease (CDC) classification was C-3 secondary to
an AIDS diagnosis at age 5 for recurrent bacterial infections.
However, he had been clinically stable on HAART for many
years. The change to a TDF-based regimen was prompted by
the patient’s significant emotional distress secondary to severe
facial lipodystrophy. At the time of the regimen change, to
tenofovir=emtricitabine (Truvada, Gilead Sciences, Foster
City, CA) 300mg=200mg once daily and lopinavir=ritonavir
(Kaletra, Abbott Laboratories, Abbott Park, IL) 133.3mg=
33.3mg three tablets twice daily, the patient’s plasma viral
RNA level had been undetectable (<75 copies per milliliter by
HIV RNA polymerase chain reacton [PCR]) for more than 1
year. His absolute CD4þ cell count and percentage were 314
cells=mm3 and 21%. The patient had been adopted in infancy
and family history was unknown. He smoked one half-pack
of cigarettes daily and denied other illicit substance use. At ini-
tiation of TDF, the patient was normotensive and not anemic.
His baseline serum creatinine concentration at initiation of
TDF was 0.9mg=dL, with an estimated CrCl of 121mL=min.
Five months after initiating TDF, the patient’s serum creati-
nine concentration began to slowly rise (Fig. 1), reaching a
level of 2.0mg=dL (estimated CrCl: 56.5mL=min) 1 year after
initiation of TDF. While discontinuing the regimen was dis-
cussed at the time, TDF-based therapy was continued due to
the limited treatment options available to this patient with
multi-drug–resistant HIV and the achievement of virologic
suppression on TDF.
Seventeen months after initiation of TDF, the patient’s se-
rum creatinine concentration abruptly rose to 3.2mg=dL
(CrCl: 35.9) from a level of 2.3mg=dL the previous month. His
blood pressure was 116=70mm Hg. At this time all antire-
troviral medications were discontinued. A urinalysis revealed
greater than 3000mg=dL proteinuria. A renal ultrasound re-
vealed markedly echogenic kidneys with a lack of cortico-
medullary differentiation. The overall appearance was not
consistent with HIV nephropathy because the kidneys were
not enlarged. A renal biopsy was not obtained, as the results
would not have altered the treatment plan. On the basis of
clinical presentation, laboratory values, and ultrasound re-
sults, the patient was diagnosed with chronic kidney disease
stage 4 secondary to nephrotoxic medications and=or HIV
nephropathy.
After discontinuation of TDF, the patient’s renal function
failed to improve. He developed hypertension and anemia 3
months later. His serum creatinine concentration has contin-
ued to rise, prompting initiation of hemodialysis. He is cur-
rently undergoing evaluation for renal transplantation.
Patient 2
A 16-year-old African American male with perinatally ac-
quired HIV presented with chronic knee pain and limp. He
was found to have rickets with hypophosphatemia while on
a TDF-based HAART regimen. The patient was started on
tenofovir=emtricitabine (Truvada) 300mg=200mg once daily
and lopinavir=ritonavir (Kaletra) 133.3mg=33.3mg three
tablets twice daily after poor adherence to his previous regi-
men. His CDC classification was B-2 secondary to lympho-
cytic interstitial pneumonitis at age 3. His family history was
unknown. The patient was a nonsmoker, and denied other
illicit substance use. At the time of the regimen change, the
patient’s plasma viral RNA level was 170 copies per milliliter.
His absolute CD4þ cell count and percentage were 895 cells=
mm3 and 55%. The patient was not anemic. His blood pres-
sure was 120=54mmHg. Shortly after initiating TDF-based
HAART, the patient transferred care to another provider due
to transportation issues.
The patient developed knee pain and difficulty walking 2
years after starting TDF, and returned to our clinic for a sec-
ond opinion. On physical examination, he had bilateral genu
FIG. 1. Laboratory values for
tenofovir.
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valgum, with no swelling or decrease in range of motion. A
dual-energy x-ray absorptiometry (DEXA) scan revealed se-
verely reduced lumbar bone mineral density (BMD), with a
z score of 3.4 standard deviation (SD). Plain film radio-
graphs of the knees showed rickets with abnormal physes
and metaphyses. Serum laboratory values were notable for
hypophosphatemia (2.3mg=dL), hypouricemia (1.8mg=dL),
normal creatinine concentration (1.0mg=dL, estimated GFR:
104mL=min), and increased alkaline phosphatase (1438mg=
dL). Serum parathyroid hormone, calcium, bicarbonate, 25-
hydroxy vitamin D, and 1,25-vitamin D were within normal
limits. Urine studies revealed a slightly increased to creatinine
ratio of 0.9. The b2-microglobulin (B2MG) concentration
(49,244 mg=dL) and B2MG=creatinine ratio (96,557 mg=g) were
markedly elevated, fractional tubular reabsorption of phos-
phate was decreased (76%), and he had glucosuria, indicating
tubular damage. Blood pressures and hemoglobin were nor-
mal. The patient was diagnosed with rickets caused by
phosphate wasting with evidence of renal and tubular injury,
most likely secondary toTDF-associatednephrotoxicity. Three
months later his serum creatinine had increased to 1.3mg=dL,
serum phosphorus remained low at 2.1mg=dL, and serum
alkaline phosphatase had increased to 1988 U=L. He admitted
that he was not adhering to the phosphate and calcitriol
treatment.
Discussion
While numerous cases of TDF-associated renal dysfunction
have been described in adults, few pediatric cases have been
reported, all of which have been reversible acute renal fail-
ure.13,14 Our cases differ significantly from the previous cases
in presentation and course of illness.
Our first patient represents a probable case of TDF-
associated nephrotoxicity, presenting as a proximal tubular
protein-wasting nephropathy. The structural damage evident
on ultrasound raises the possibility of preexisting renal dis-
ease. However, the normal urinalysis 3 months after begin-
ning TDF therapy suggests that the patient’s proteinuria
developed in the context of TDF use.
The differential diagnosis of renal failure in HIV-infected
patients includes HIV-associated nephropathy (HIVAN),
membranoproliferativeglomerulonephritisandother immune
complex glomerulonephritides, drug-induced renal disease
secondary to direct nephrotoxicity or acute interstitial nephri-
tis, as well as the myriad of other causes affecting the general
population.15 HIVAN is the most common cause of renal in-
sufficiency in patients with HIV, disproportionately affecting
patients of African descent. The typical presentation for HI-
VAN involves rapidly rising creatinine levels accompanied by
nephrotic-range proteinuria.15,16
While our patient’s history suggests some degree of un-
derlying renal disease, his presentation is atypical for HIVAN.
Most notably, HIV nephropathy generally occurs at CD4 cell
counts less than 200 cells=mm3, and high viral loads.17 With
the exception of one value of 184 cells=mm3 3 months after
initiating this regimen, our patient’s CD4 cell count has re-
mained above 300 cells=mm3 and greater than 20% for the
past 10 years. Similarly his level of viremia has remained
largely undetectable for 7 years. In a setting of near-normal
CD4 counts, suppressed viral load, normal kidney size, and
normal urinalysis until initiation of TDF, we believe that HI-
VAN is unlikely as the sole etiology for his irreversible renal
failure.
A point of particular importance is the apparent irrevers-
ibility of the renal damage. In adult reports, 81%–94% of
patients returned to baseline creatinine values upon discon-
tinuation of TDF.6,8,9 All previously reported pediatric cases
returned to baseline renal function.13,14 In our patient, the
nephropathy has failed to resolve over the 2-year period since
discontinuation of TDF, necessitating dialysis and possible
kidney transplantation.
TDF remains an off-label medication for pediatric patients.
However, it is a vital component of salvage regimens for
heavily treatment-experienced children and adolescents.18 In
this particular patient, the choice to use TDF was based on
genotypic assay of his multi-drug–resistant virus, as well as
the lipodystrophic adverse effects of his prior regimen. Early
safety and efficacy trials found TDF to be associated bothwith
less lipodystrophy than other NRTI-based regimens and with
an increased genetic barrier to resistance.3 These qualities
make it an excellent choice for salvage therapy in patients
with complicated HAART treatment histories.
Our second patient’s presentation of rickets with hypo-
phosphatemia has not been previously reported in the liter-
ature. Although clinically significant changes in bone mineral
density (BMD) in pediatric patients have been associated with
TDF use, this is the first report of TDF-associated rickets.18,19
The severity of our patient’s loss of BMD underscore the need
for regular monitoring of BMD in pediatric patients receiving
TDF.
Adult and pediatric trials have reported a significant
association between hypophosphatemia and TDF-based
HAART.20,21 Renal reabsorption of phosphate occurs at the
proximal tubule, the segment of the nephron most commonly
affected in TDF-associated nephrotoxicity. Our patient’s pre-
sentation of rickets with proximal renal tubular dysfunction
as evidenced by hypophosphatemia, hypouricemia, phos-
phate wasting, glucosuria, and high urinary concentrations of
B2MG but normal PTH, and vitamin D levels suggest that a
drug-induced proximal tubulopathy is the likely etiology. The
patient’s high urinary levels of B2MG also implicate TDF as
the likely causative agent. Previous studies have found an
association between high B2MG levels and TDF usage in HIV-
infected adults and children, suggesting that B2MG may be a
sensitive marker of TDF-associated renal dysfunction.21,22
These two cases emphasize the need for safe and effective
antiretroviral agents for use in pediatric salvage therapy.
While TDF is a preferred agent for initial therapy for HIV-
infected adults, it has not been approved for use in patients
less than 18 years of age. Safety and pharmacokinetic data are
limited for the younger age group with a paucity of infor-
mation about the incidence of TDF-associated nephrotoxicity
in this population. For patients on a TDF-based regimen in
combination with RTV or ddI, particular attention must be
paid to ongoing renal function, and drug doses should be
tailored to minimize risk of toxicity while still achieving op-
timal virologic control. Finally, baseline and ongoing moni-
toring of bone mineral density with DEXA scanning may
help identify children at risk for TDF-associated rickets or
osteopenia. Further studies are warranted to better charac-
terize the renal safety profile of TDF in children, and to guide
ongoing management of children on TDF-based salvage
therapy.
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